Last week, NIH Director Francis S. Collins issued a statement about the pervasive problem of sexual harassment in science and reaffirmed NIH’s commitment to address it. He noted that NIH is working to bolster its policies and practices to foster a culture of respect wherever NIH research activities are conducted, and to ensure that sexual harassment is not tolerated or ignored.
NIH has launched a new website on anti-sexual harassment activities. I encourage you to explore the site and become familiar with NIH’s policies, practices, and initiatives.
Consistent with NIGMS’ strong commitment to research training, the Institute recently announced that applications for our predoctoral T32 training programs must include in their required institutional support letters information about the institution’s policies and procedures to prevent discriminatory harassment and respond appropriately to allegations or findings of discriminatory harassment. Moving forward, NIGMS will require this information in institutional support letters for applications for all of our training programs.
We are delighted that three long-time NIGMS grantees have been recognized by the 2018 Lasker Awards . The awards highlight fundamental biological discoveries to draw attention to the importance of public support of science.
Michael Grunstein of the University of California, Los Angeles, and C. David Allis of Rockefeller University, received the 2018 Albert Lasker Basic Medical Research Award for “discoveries elucidating how gene expression is influenced by chemical modifications of histones—the proteins that package DNA within chromosomes.” NIGMS funded Grunstein’s work on the establishment and spreading of silent chromatin from 1977 to 2012. His research led to the generation of the first histone mutations in yeast and the first demonstration that chemical modification of specific ends of histones could turn gene expression on or off. Allis identified and characterized enzymes that add, remove, and read histone modifications. His work led to the hypothesis of a histone code that, when mis-read, can lead to disease. NIGMS has funded Allis since 1988.
Joan Argetsinger Steitz of Yale University received the 2018 Lasker-Koshland Special Achievement Award in Medical Science for “four decades of leadership in biomedical science—exemplified by pioneering discoveries in RNA biology, generous mentorship of budding scientists, and vigorous and passionate support of women in science.” Steitz’s pioneering research helped reveal the function of small pieces of RNA that are not used for making proteins. These molecules, including small nuclear ribonucleoproteins (snRNPs), help regulate gene activity. In doing so, they—like histone modifications—have a major impact on health and disease. NIGMS funded her research from 1975 to 2014. The Lasker-Koshland Award further recognizes Steitz’s long record of mentoring the next generation of scientific leaders and her effective and tireless work as an advocate for women in science.
We congratulate all of the recipients on these well-deserved honors.
We’re recruiting for an accomplished scientist with experience in the pharmacological sciences to join the Pharmacological and Physiological Sciences (PPS) Branch of the Division of Pharmacology, Physiology, and Biological Chemistry. The successful applicant will have responsibility for scientific and administrative management of a portfolio of grants, both research and training, in the Division.
The PPS Branch supports research studies ranging from the molecular to cellular to organismal, which can be basic or clinical in nature. This position offers stewardship of grant awards related to modern approaches to examining the effects of drugs on the body and the body’s effects on drugs, as well as how these effects vary from individual to individual. This includes investigations of the absorption, transport, distribution, metabolism, biotransformation, toxicity, and excretion of drugs, as well as determinants and models of pharmacokinetics. The portfolio also includes investigation of drug delivery strategies and the packaging and delivery of molecules and biologics, with an emphasis on drug release and kinetics.
Are you applying for the NIGMS Predoctoral Institutional Research Training Grant (T32) – PAR-17-341? If so, it’s important you note revisions to our FOA instructions that clarify application requirements. We have also added a new requirement concerning institutional responsibilities related to harassment. We encourage you to read the full NIH Guide notice, published on August 23, 2018. Key points include:
You may send questions to us (Mercedes Rubio or Patrick H. Brown) before the webinar or post them live in the chat box during the event. If you’re away from your computer, you can access the webinar from a mobile device or listen to a voice-only option by dialing 1-800-857-5163 from anywhere in the United States or Canada and entering the participant passcode 2222558.
NIGMS Staff Participating in the August 16 Webinar:
Mercedes Rubio, Bridges to the Baccalaureate Program Director
Patrick H. Brown, Bridges to the Doctorate Program Director
Rebecca Johnson, Scientific Review Officer
Justin Rosenzweig, Grants Management Specialist
Although NIGMS is not the only source of federal funding for sepsis research, the Institute supports a substantial portfolio of research that includes both fundamental and clinical studies, from the molecular to the organismal, that emphasizes the host’s response rather than causative factors such as infection or injury. In an effort to more rapidly move NIGMS’ sepsis research program and its translation forward, we’ve issued a Request for Information (RFI) to obtain feedback, comments, novel ideas, and strategies that address the challenges and opportunities in sepsis research to accelerate advances in detection of and treatment for this condition.
A recent analysis by NIGMS staff has uncovered some promising results for women entering academic positions in the biomedical sciences. The study, which published today in the Proceedings of the National Academy of Sciences (PNAS), found that once men and women receive their first major NIH grant, their funding longevity is similar. The data contradict the common assumption that, across all career stages, women are at a large disadvantage compared to men.
NIGMS Deputy Director Judith H. Greenberg on key findings in the paper.
The results of the analysis should be encouraging for women interested in becoming independent investigators, since the likelihood of sustaining NIH grant support may be better than commonly perceived. You can read the full study, “NIH Funding Longevity by Gender,” in the current edition of PNAS.
The award recognizes outstanding mentors whose efforts encourage the next generation of innovators and help to develop a science and engineering workforce that reflects the diverse talent of our nation, key goals of a number of programs here at NIGMS.
Awardees received a Presidential certificate and a $10,000 grant to continue their mentoring activities at a ceremony in Washington, D.C., last month. Please join me in congratulating all winners of this prestigious honor.
I’m pleased to announce that Ming Lei will join NIGMS later this month as the new director of our Division for Research Capacity Building. Ming is a molecular geneticist with extensive experience overseeing fellowship, career development, and training and education grant programs.Ming is currently deputy director of the Center for Cancer Training and chief of the Cancer Training Branch at the National Cancer Institute, which he joined in 2008 as a program director. His experience before that includes leading the Genes and Genome Cluster in the Division of Molecular and Cellular Biosciences at the National Science Foundation, serving as an associate professor of microbiology at the Medical College of Wisconsin, and working as a research scientist in the Division of Biotechnology at the Monsanto Corporation in St. Louis, Missouri.
Ming’s expertise in managing far-reaching and complex programs, and his ability to effectively engage with scientists and other stakeholders, make him an ideal choice for this key position and a valuable addition to our senior leadership team.
NIGMS is committed to supporting a wide-ranging portfolio of biomedically relevant fundamental research. As we discussed in a previous Feedback Loop post, we see this approach as the best way to increase our understanding of life. For many years, one important dimension of diversity in our scientific portfolio—the organisms scientists use to conduct their research—was limited by technical considerations. However, recent advances such as the decreasing cost of genome sequencing and the development of the CRISPR system for genetic modification now make it possible to use an expanded range of research organisms.